1	Reduction	reduction	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	tumour	tumour	_	_	_	_	_	_	_
4	necrosis	necrosis	_	_	_	_	_	_	_
5	factor	factor	_	_	_	_	_	_	_
6	alpha	alpha	_	_	_	_	_	_	_
7	expression	expression	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	signalling	signalling	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	peripheral	peripheral	_	_	_	_	_	_	_
12	blood	blood	_	_	_	_	_	_	_
13	mononuclear	mononuclear	_	_	_	_	_	_	_
14	cells	cell	_	_	_	_	_	_	_
15	from	from	_	_	_	_	_	_	_
16	patients	patient	_	_	_	_	_	_	_
17	with	with	_	_	_	_	_	_	_
18	thalassaemia	thalassaemia	_	_	_	_	_	_	_
19	or	or	_	_	_	_	_	_	_
20	sickle	sickle	_	_	_	_	_	_	_
21	cell	cell	_	_	_	_	_	_	_
22	anaemia	anaemia	_	_	_	_	_	_	_
23	upon	upon	_	_	_	_	_	_	_
24	treatment	treatment	_	_	_	_	_	_	_
25	with	with	_	_	_	_	_	_	_
26	desferrioxamine	desferrioxamine	_	_	_	_	_	_	_
27	.	.	_	_	_	_	_	_	_

1	Recent	recent	_	_	_	_	_	_	_
2	evidence	evidence	_	_	_	_	_	_	_
3	indicates	indicate	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	rate	rate	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	progression	progression	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	the	the	_	_	_	_	_	_	_
11	HIV-1	HIV-1	_	_	_	_	_	_	_
12	disease	disease	_	_	_	_	_	_	_
13	is	be	_	_	_	_	_	_	_
14	significantly	significantly	_	_	_	_	_	_	_
15	reduced	reduce	_	_	_	_	_	_	_
16	in	in	_	_	_	_	_	_	_
17	thalassaemia	thalassaemia	_	_	_	_	_	_	_
18	major	major	_	_	_	_	_	_	_
19	patients	patient	_	_	_	_	_	_	_
20	upon	upon	_	_	_	_	_	_	_
21	treatment	treatment	_	_	_	_	_	_	_
22	with	with	_	_	_	_	_	_	_
23	high	high	_	_	_	_	_	_	_
24	doses	dose	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	desferrioxamine	desferrioxamine	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	DFX	DFX	_	_	_	_	_	_	_
29	)	)	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	authors	author	_	_	_	_	_	_	_
3	have	have	_	_	_	_	_	_	_
4	previously	previously	_	_	_	_	_	_	_
5	demonstrated	demonstrate	_	_	_	_	_	_	_
6	that	that	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	vitro	vitro	_	_	_	_	_	_	_
9	exposure	exposure	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	mononuclear	mononuclear	_	_	_	_	_	_	_
12	cells	cell	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	DFX	DFX	_	_	_	_	_	_	_
15	decreases	decrease	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	bioavailability	bioavailability	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	tumour	tumour	_	_	_	_	_	_	_
20	necrosis	necrosis	_	_	_	_	_	_	_
21	factor	factor	_	_	_	_	_	_	_
22	alpha	alpha	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
25	)	)	_	_	_	_	_	_	_
26	which	which	_	_	_	_	_	_	_
27	has	have	_	_	_	_	_	_	_
28	a	a	_	_	_	_	_	_	_
29	stimulatory	stimulatory	_	_	_	_	_	_	_
30	effect	effect	_	_	_	_	_	_	_
31	on	on	_	_	_	_	_	_	_
32	HIV-1	HIV-1	_	_	_	_	_	_	_
33	replication	replication	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	this	this	_	_	_	_	_	_	_
3	study	study	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	therefore	therefore	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
8	bioavailability	bioavailability	_	_	_	_	_	_	_
9	from	from	_	_	_	_	_	_	_
10	mononuclear	mononuclear	_	_	_	_	_	_	_
11	cells	cell	_	_	_	_	_	_	_
12	isolated	isolate	_	_	_	_	_	_	_
13	from	from	_	_	_	_	_	_	_
14	10	10	_	_	_	_	_	_	_
15	patients	patient	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	thalassaemia	thalassaemia	_	_	_	_	_	_	_
18	or	or	_	_	_	_	_	_	_
19	sickle	sickle	_	_	_	_	_	_	_
20	cell	cell	_	_	_	_	_	_	_
21	anaemia	anaemia	_	_	_	_	_	_	_
22	given	give	_	_	_	_	_	_	_
23	DFX	DFX	_	_	_	_	_	_	_
24	as	as	_	_	_	_	_	_	_
25	compared	compare	_	_	_	_	_	_	_
26	to	to	_	_	_	_	_	_	_
27	10	10	_	_	_	_	_	_	_
28	untreated	untreated	_	_	_	_	_	_	_
29	subjects	subject	_	_	_	_	_	_	_
30	has	have	_	_	_	_	_	_	_
31	been	be	_	_	_	_	_	_	_
32	evaluated	evaluate	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	Evidence	evidence	_	_	_	_	_	_	_
2	is	be	_	_	_	_	_	_	_
3	presented	present	_	_	_	_	_	_	_
4	showing	show	_	_	_	_	_	_	_
5	that	that	_	_	_	_	_	_	_
6	DFX	DFX	_	_	_	_	_	_	_
7	treatment	treatment	_	_	_	_	_	_	_
8	reduces	reduce	_	_	_	_	_	_	_
9	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
10	bioavailability	bioavailability	_	_	_	_	_	_	_
11	(	(	_	_	_	_	_	_	_
12	P<0.05	p<0.05	_	_	_	_	_	_	_
13	)	)	_	_	_	_	_	_	_
14	by	by	_	_	_	_	_	_	_
15	inhibiting	inhibit	_	_	_	_	_	_	_
16	its	its	_	_	_	_	_	_	_
17	steady	steady	_	_	_	_	_	_	_
18	state	state	_	_	_	_	_	_	_
19	(	(	_	_	_	_	_	_	_
20	P<0.05	p<0.05	_	_	_	_	_	_	_
21	)	)	_	_	_	_	_	_	_
22	and	and	_	_	_	_	_	_	_
23	by	by	_	_	_	_	_	_	_
24	enhancing	enhance	_	_	_	_	_	_	_
25	its	its	_	_	_	_	_	_	_
26	inactivation	inactivation	_	_	_	_	_	_	_
27	through	through	_	_	_	_	_	_	_
28	binding	binding	_	_	_	_	_	_	_
29	to	to	_	_	_	_	_	_	_
30	soluble	soluble	_	_	_	_	_	_	_
31	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
32	receptor	receptor	_	_	_	_	_	_	_
33	type	type	_	_	_	_	_	_	_
34	II	ii	_	_	_	_	_	_	_
35	(	(	_	_	_	_	_	_	_
36	P<0.05	P<0.05	_	_	_	_	_	_	_
37	)	)	_	_	_	_	_	_	_
38	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	also	also	_	_	_	_	_	_	_
3	show	show	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	DFX	DFX	_	_	_	_	_	_	_
6	treatment	treatment	_	_	_	_	_	_	_
7	limits	limit	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	vivo	vivo	_	_	_	_	_	_	_
11	activation	activation	_	_	_	_	_	_	_
12	of	of	_	_	_	_	_	_	_
13	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	a	a	_	_	_	_	_	_	_
16	transcription	transcription	_	_	_	_	_	_	_
17	factor	factor	_	_	_	_	_	_	_
18	involved	involve	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	both	both	_	_	_	_	_	_	_
21	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
22	gene	gene	_	_	_	_	_	_	_
23	transcription	transcription	_	_	_	_	_	_	_
24	and	and	_	_	_	_	_	_	_
25	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
26	signalling	signalling	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	P<0.005	p<0.005	_	_	_	_	_	_	_
29	)	)	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	conclude	conclude	_	_	_	_	_	_	_
3	that	that	_	_	_	_	_	_	_
4	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
5	bioavailability	bioavailability	_	_	_	_	_	_	_
6	and	and	_	_	_	_	_	_	_
7	signalling	signalling	_	_	_	_	_	_	_
8	are	be	_	_	_	_	_	_	_
9	impaired	impaired	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	patients	patient	_	_	_	_	_	_	_
12	upon	upon	_	_	_	_	_	_	_
13	DFX	DFX	_	_	_	_	_	_	_
14	treatment	treatment	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	mechanism	mechanism	_	_	_	_	_	_	_
3	may	may	_	_	_	_	_	_	_
4	contribute	contribute	_	_	_	_	_	_	_
5	to	to	_	_	_	_	_	_	_
6	delayed	delay	_	_	_	_	_	_	_
7	progression	progression	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	HIV-1	HIV-1	_	_	_	_	_	_	_
11	infection	infection	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	vivo	vivo	_	_	_	_	_	_	_
14	.	.	_	_	_	_	_	_	_

1	Copyright	Copyright	_	_	_	_	_	_	_
2	1999	1999	_	_	_	_	_	_	_
3	Academic	Academic	_	_	_	_	_	_	_
4	Press	Press	_	_	_	_	_	_	_
5	.	.	_	_	_	_	_	_	_

